Advaxis Shares Outstanding 2007-2021 | ADXS

Advaxis shares outstanding from 2007 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Advaxis Annual Shares Outstanding
(Millions of Shares)
2020 61
2019 15
2018 3
2017 3
2016 2
2015 2
2014 1
2013 0
2012 0
2011 0
2010 0
2009 0
2008 0
2007 0
2006 0
Advaxis Quarterly Shares Outstanding
(Millions of Shares)
2021-07-31 146
2021-04-30 123
2021-01-31 84
2020-10-31 61
2020-07-31 62
2020-04-30 61
2020-01-31 52
2019-10-31 15
2019-07-31 10
2019-04-30 6
2019-01-31 5
2018-10-31 3
2018-07-31 4
2018-04-30 3
2018-01-31 3
2017-10-31 3
2017-07-31 3
2017-04-30 3
2017-01-31 3
2016-10-31 2
2016-07-31 2
2016-04-30 2
2016-01-31 2
2015-10-31 2
2015-07-31 2
2015-04-30 2
2015-01-31 1
2014-10-31 1
2014-07-31 1
2014-04-30 1
2014-01-31 1
2013-10-31 0
2013-07-31 0
2013-04-30 0
2013-01-31 0
2012-10-31 0
2012-07-31 0
2012-04-30 0
2012-01-31 0
2011-10-31 0
2011-07-31 0
2011-04-30 0
2011-01-31 0
2010-10-31 0
2010-07-31 0
2010-04-30 0
2010-01-31 0
2009-10-31 0
2009-07-31 0
2009-04-30 0
2009-01-31 0
2008-10-31 0
2008-07-31 0
2008-04-30 0
2008-01-31 0
2007-10-31 0
2007-07-31 0
2007-04-30 0
2007-01-31 0
2006-07-31 0
2006-04-30 0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.073B $0.000B
Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57